These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

190 related articles for article (PubMed ID: 37946220)

  • 1. Assessment of probiotic strain Lactobacillus acidophilus LB supplementation as adjunctive management of attention-deficit hyperactivity disorder in children and adolescents: a randomized controlled clinical trial.
    Elhossiny RM; Elshahawy HH; Mohamed HM; Abdelmageed RI
    BMC Psychiatry; 2023 Nov; 23(1):823. PubMed ID: 37946220
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Atomoxetine improved attention in children and adolescents with attention-deficit/hyperactivity disorder and dyslexia in a 16 week, acute, randomized, double-blind trial.
    Wietecha L; Williams D; Shaywitz S; Shaywitz B; Hooper SR; Wigal SB; Dunn D; McBurnett K
    J Child Adolesc Psychopharmacol; 2013 Nov; 23(9):605-13. PubMed ID: 24206099
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A Pilot Randomized Control Trial With the Probiotic Strain
    Kumperscak HG; Gricar A; Ülen I; Micetic-Turk D
    Front Psychiatry; 2020; 11():181. PubMed ID: 32256407
    [No Abstract]   [Full Text] [Related]  

  • 4. Effect of probiotics as an adjunctive therapy with Ritalin among ADHD children and adolescents: a triple-blind randomized controlled trial.
    Sangsefidi ZS; Sangsefidi ZS; Moharreri F; Heydari Yazdi AS; Eslami S; Emadzadeh B; Ghorani B; Sarabi-Jamab M; Farahmand A; Modiri Dovom A; Ghanaei A; Emadzadeh M
    Nutr Neurosci; 2024 Aug; ():1-10. PubMed ID: 39163291
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A Phase III, Randomized, Double-Blind, Placebo-Controlled Trial Assessing the Efficacy and Safety of Viloxazine Extended-Release Capsules in Adults with Attention-Deficit/Hyperactivity Disorder.
    Nasser A; Hull JT; Chaturvedi SA; Liranso T; Odebo O; Kosheleff AR; Fry N; Cutler AJ; Rubin J; Schwabe S; Childress A
    CNS Drugs; 2022 Aug; 36(8):897-915. PubMed ID: 35896943
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy and safety of atomoxetine in childhood attention-deficit/hyperactivity disorder with comorbid oppositional defiant disorder.
    Kaplan S; Heiligenstein J; West S; Busner J; Harder D; Dittmann R; Casat C; Wernicke JF
    J Atten Disord; 2004 Oct; 8(2):45-52. PubMed ID: 15801334
    [TBL] [Abstract][Full Text] [Related]  

  • 7. An Open-Label, Randomized Trial of Methylphenidate and Atomoxetine Treatment in Children with Attention-Deficit/Hyperactivity Disorder.
    Shang CY; Pan YL; Lin HY; Huang LW; Gau SS
    J Child Adolesc Psychopharmacol; 2015 Sep; 25(7):566-73. PubMed ID: 26222447
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Atomoxetine: a new treatment for Attention Deficit/Hyperactivity Disorder (ADHD) in children and adolescents].
    Purper-Ouakil D; Fourneret P; Wohl M; Rénéric JP
    Encephale; 2005; 31(3):337-48. PubMed ID: 16142049
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Once-daily atomoxetine treatment for children with attention-deficit/hyperactivity disorder, including an assessment of evening and morning behavior: a double-blind, placebo-controlled trial.
    Kelsey DK; Sumner CR; Casat CD; Coury DL; Quintana H; Saylor KE; Sutton VK; Gonzales J; Malcolm SK; Schuh KJ; Allen AJ
    Pediatrics; 2004 Jul; 114(1):e1-8. PubMed ID: 15231966
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Differential impact of methylphenidate and atomoxetine on sustained attention in youth with attention-deficit/hyperactivity disorder.
    Bédard AC; Stein MA; Halperin JM; Krone B; Rajwan E; Newcorn JH
    J Child Psychol Psychiatry; 2015 Jan; 56(1):40-8. PubMed ID: 24942409
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Response inhibition and emotional cognition improved by atomoxetine in children and adolescents with ADHD: The ACTION randomized controlled trial.
    Griffiths KR; Leikauf JE; Tsang TW; Clarke S; Hermens DF; Efron D; Williams LM; Kohn MR
    J Psychiatr Res; 2018 Jul; 102():57-64. PubMed ID: 29674270
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Coenzyme Q10 in the Treatment of Attention Deficit Hyperactivity Disorder in Children: A Randomized Controlled Trial.
    Gamal F; El Agami O; Salamah A
    CNS Neurol Disord Drug Targets; 2022; 21(8):717-723. PubMed ID: 34819012
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Behavioral and cognitive effects of docosahexaenoic acid in drug-naïve children with attention-deficit/hyperactivity disorder: a randomized, placebo-controlled clinical trial.
    Crippa A; Tesei A; Sangiorgio F; Salandi A; Trabattoni S; Grazioli S; Agostoni C; Molteni M; Nobile M
    Eur Child Adolesc Psychiatry; 2019 Apr; 28(4):571-583. PubMed ID: 30246216
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of vitamin D supplementation as adjunctive therapy to methylphenidate on ADHD symptoms: A randomized, double blind, placebo-controlled trial.
    Mohammadpour N; Jazayeri S; Tehrani-Doost M; Djalali M; Hosseini M; Effatpanah M; Davari-Ashtiani R; Karami E
    Nutr Neurosci; 2018 Apr; 21(3):202-209. PubMed ID: 27924679
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Atomoxetine-Related Change in Sluggish Cognitive Tempo Is Partially Independent of Change in Attention-Deficit/Hyperactivity Disorder Inattentive Symptoms.
    McBurnett K; Clemow D; Williams D; Villodas M; Wietecha L; Barkley R
    J Child Adolesc Psychopharmacol; 2017 Feb; 27(1):38-42. PubMed ID: 27845858
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Atomoxetine hydrochloride in the treatment of children and adolescents with attention-deficit/hyperactivity disorder and comorbid oppositional defiant disorder: A placebo-controlled Italian study.
    Dell'Agnello G; Maschietto D; Bravaccio C; Calamoneri F; Masi G; Curatolo P; Besana D; Mancini F; Rossi A; Poole L; Escobar R; Zuddas A;
    Eur Neuropsychopharmacol; 2009 Nov; 19(11):822-34. PubMed ID: 19716683
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of Atomoxetine on the Cognitive Functions in Treatment of Attention Deficit Hyperactivity Disorder in Children with Congenital Hypothyroidism: A Pilot Study.
    Yang R; Gao W; Li R; Zhao Z
    Int J Neuropsychopharmacol; 2015 Apr; 18(8):. PubMed ID: 25896257
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Attention Training Improves Executive Functions and Ameliorates Behavioral Symptoms in Children with Attention-Deficit Hyperactivity Disorder: Implication of Tele-Cognitive-Rehabilitation in the Era of Coronavirus Disease.
    Nejati V; Derakhshan Z
    Games Health J; 2024 Feb; 13(1):40-49. PubMed ID: 38300525
    [No Abstract]   [Full Text] [Related]  

  • 19. A randomized, double-blind, placebo-controlled clinical trial on once-daily atomoxetine in Taiwanese children and adolescents with attention-deficit/hyperactivity disorder.
    Gau SS; Huang YS; Soong WT; Chou MC; Chou WJ; Shang CY; Tseng WL; Allen AJ; Lee P
    J Child Adolesc Psychopharmacol; 2007 Aug; 17(4):447-60. PubMed ID: 17822340
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Predictors of relapse or maintenance of response in pediatric and adult patients with attention-deficit/hyperactivity disorder following discontinuation of long-term treatment with atomoxetine.
    Thome J; Dittmann RW; Greenhill LL; Lipsius S; Tanaka Y; Bushe C; Escobar R; Heinloth AN; Upadhyaya H
    Atten Defic Hyperact Disord; 2017 Dec; 9(4):219-229. PubMed ID: 28477289
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.